Sartorius Stedim Biotech agreed to buy Polyplus, a maker of components for cell and gene therapies, for about €2.4 billion ($2.6 billion) from a group of private investors. The deal would bolster ...

Sartorius announced the 2.4 billion euro acquisition of Polyplus. Polyplus is producing transfection reagents and generates 100 million euros in revenues. The acquisition appears to be very expensive ...

Warburg Pincus has made an investment in Polyplus, a developer of technology used in gene and cell therapy. Warburg’s investment in Polyplus puts the latter at a valuation of more than 500 million ...

March 31 (Reuters) - Sartorius SATG.DE said on Friday it would acquire France-based biotechnology company Polyplus for 2.4 billion euros ($2.62 billion) from private investors including Archimed and ...

Polyplus will be acquired by Sartorius for around €2.4bn Sartorius will receive a bridge loan facility from JP Morgan to finance the transaction Archimed and Warburg Pincus first invested in Polyplus ...

Polyplus-transfection(R) SA, the leading biotechnology company that supports gene and cell therapy by supplying innovative transfection solutions, today announces the availability of the first ...

(RTTNews) - Sartorius (SARTF), through its subgroup Sartorius Stedim Biotech, has signed an agreement to acquire Polyplus for approximately 2.4 billion euros from private investors including ARCHIMED ...

Strasbourg-based Polyplus-transfection started construction of Vectura, a new 4,000-square-meter facility which is being built to enable the company to continue to tap into the exponential growth in ...

Polyplus, which provides upstream solutions for biologic and cell and gene therapy production from research to commercial grade, introduced its transgene plasmid engineering services for viral vector ...